Oppenheimer & CO Inc Ocugen, Inc. Transaction History
Oppenheimer & CO Inc
- $7.83 Billion
- Q3 2025
A detailed history of Oppenheimer & CO Inc transactions in Ocugen, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 43,805 shares of OCGN stock, worth $52,127. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,805
Previous 43,805
-0.0%
Holding current value
$52,127
Previous $42,000
69.05%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding OCGN
# of Institutions
106Shares Held
60.4MCall Options Held
531KPut Options Held
433K-
Black Rock Inc. New York, NY17.9MShares$21.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$18.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.16MShares$4.95 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA4.15MShares$4.94 Million0.31% of portfolio
-
Geode Capital Management, LLC Boston, MA3.68MShares$4.38 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $258M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...